918638-44-5Relevant articles and documents
Rational Adaptation of L3MBTL1 Inhibitors to Create Small-Molecule Cbx7 Antagonists
Simhadri, Chakravarthi,Daze, Kevin D.,Douglas, Sarah F.,Milosevich, Natalia,Monjas, Leticia,Dev, Amarjot,Brown, Tyler M.,Hirsch, Anna K. H.,Wulff, Jeremy E.,Hof, Fraser
supporting information, p. 1444 - 1456 (2019/08/02)
Chromobox homolog 7 (Cbx7) is an epigenetic modulator that is an important driver of multiple cancers. It is a methyl reader protein that operates by recognizing and binding to methylated lysine residues on specific partners. Herein we report our efforts to create low-molecular-weight inhibitors of Cbx7 by making rational structural adaptations to inhibitors of a different methyl reader protein, L3MBTL1, inhibitors that had previously been reported to be inactive against Cbx7. We evaluated each new inhibitor for Cbx7 inhibition by fluorescence polarization assay, and also confirmed the binding of selected inhibitors to Cbx7 by saturation-transfer difference NMR spectroscopy. This work identified multiple small-molecule inhibitors with modest (IC50: 257–500 μm) potency.
Development and characterization of biphenylsulfonamides as novel inhibitors of bone resorption
Greig, Iain R.,Idris, Aymen I.,Ralston, Stuart H.,Van't Hof, Rob J.
, p. 7487 - 7492 (2007/10/03)
Increased osteoclastic bone resorption plays a central role in the pathogenesis of many bone diseases, and osteoclast inhibitors are the most widely used treatments for these diseases. We have identified and characterized a series of novel biphenylsulfona
